

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EuroEyes International Eye Clinic Limited**

**德視佳國際眼科有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1846)**

### **POSITIVE PROFIT ALERT**

This announcement is made by EuroEyes International Eye Clinic Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 (the “**Interim Period**”) and other information currently available to the Board, the Group expects to record a profit attributable to owners of the Company in the range of HK\$63.0 million to HK\$66.0 million due to an increase in revenue by 69% from provision of vision correction services, as compared to that of the corresponding period in 2020, a profit attributable to owners of the Company in the amount of approximately HK\$18.2 million, representing an increase of approximately 259%.

Based on the currently available information, the expected significant increase was mainly attributable to (i) the strong growth of the total number of eye surgeries performed by the Group; and (ii) the enhancement of the utilization rate of our existing clinics which resulted in a substantial increase in both revenue and gross profit being recognised during the Interim Period.

The Company is still in the process of finalising the consolidated financial results for the Interim Period. The information contained in this announcement is only a preliminary assessment by the Board based on the information currently available and the unaudited consolidated management accounts of the Group for the Interim Period, which have not been audited or reviewed by the Company’s external auditor or the audit committee of the Board. The actual results of the Group for the Interim Period may be different from what is disclosed in this announcement.

Shareholders and potential investors are advised to read carefully the announcement of the interim results of the Group for the Interim Period, which is expected to be published by the end of August 2021.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**EuroEyes International Eye Clinic Limited**  
**Dr. Jørn Slot Jørgensen**  
*Chairman and Executive Director*

Hong Kong, 6 August 2021

*As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Dr. Ralf-Christian Lerche, Mr. Jannik Jonas Slot Jørgensen as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.*